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The Fate of Spacers in the Treatment
of Periprosthetic Joint Infection
Miguel M. Gomez, MD, Timothy L. Tan, MD, Jorge Manrique, MD, Gregory K. Deirmengian, MD, and Javad Parvizi, MD, FRCS
Investigation performed at the Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania

Background: Two-stage exchange arthroplasty remains the preferred method to treat periprosthetic joint infection. The
aim of this study was to investigate the clinical course of periprosthetic joint infection following resection arthroplasty and
insertion of a spacer.
Methods: Our institutional database was used to identify 504 cases of periprosthetic joint infection (326 knees and 178
hips) treated with resection arthroplasty and spacer insertion as part of a two-stage exchange arthroplasty. A review of the
patient charts was performed to extract information relevant to the objectives of this study that included the details of the
clinical course following resection arthroplasty.
Results: The mean follow-up duration after initial spacer implantation was 56.2 months. Reimplantation occurred in the
joints of 417 (82.7%) of 504 cases. Of these 417 cases, 329 (78.9%) had a minimum one-year follow-up, and 81.4% of
these had successful treatment. The mean duration from resection arthroplasty to reimplantation was 4.2 months (range,
0.7 to 131.7 months). Sixty (11.9%) of the 504 joints required interim spacer exchange(s). Of the eighty-seven cases that did
not undergo reimplantation, six (6.9%) required amputation, ﬁve (5.7%) underwent a Girdlestone procedure, four (4.6%)
underwent arthrodesis, and seventy-two (82.8%) underwent spacer retention. Thirty-six patients died in the interstage period.
Conclusions: The commonly held belief that two-stage exchange arthroplasty carries a high success rate for the eradication of periprosthetic joint infection may need to be reexamined. A considerable number of patients undergoing the
ﬁrst stage of a two-stage procedure do not undergo a subsequent reimplantation for a variety of reasons or require an
additional spacer exchange in the interim. Reports on the success of two-stage exchange should account for the mortality
of these patients and for patients who never undergo reimplantation.
Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Peer Review: This article was reviewed by the Editor-in-Chief and one Deputy Editor, and it underwent blinded review by two or more outside experts. It was also reviewed
by an expert in methodology and statistics. The Deputy Editor reviewed each revision of the article, and it underwent a ﬁnal review by the Editor-in-Chief prior to publication.
Final corrections and clariﬁcations occurred during one or more exchanges between the author(s) and copyeditors.

T

he treatment of periprosthetic joint infection continues
to pose challenges for the orthopaedic community1. The
preferred surgical treatment of chronic periprosthetic joint
infection in North America is two-stage exchange arthroplasty that
involves removal of the prosthesis and spacer placement, followed
by reimplantation of new components during the second stage.

The reported success of two-stage exchange arthroplasty
has varied in the literature, with some studies showing a 100%
rate for infection control2-5. However, the majority of those
studies focused on the clinical outcomes following successful
reimplantation and thus may not accurately reﬂect the overall
success rate of two-stage exchange for periprosthetic joint
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is written in this work. The complete Disclosures of Potential Conﬂicts of Interest submitted by authors are always provided with the online version of
the article.
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TABLE I Patient Demographic Characteristics
Variable

All Periprosthetic Joint Infections (N = 504)

Age at the time of infection* (yr)

Knee (N = 326)

Hip (N = 178)

66.3 ± 11.3

67.3 ± 10.2

64.6 ± 13.0

66.9 ± 10.8

67.5 ± 10.0

63.2 ± 13.9

65.7 ± 11.9

67.1 ± 10.4

66.2 ± 11.6

31.4 ± 2.4

32.1 ± 2.4

30.2 ± 2.5

438 (86.9)

279 (85.6)

159 (89.3)

66 (13.1)

47 (14.4)

19 (10.7)

Primary

254 (50.4)

180 (55.2)

74 (41.6)

Revision

98 (19.4)

46 (14.1)

52 (29.2)

No data

152 (30.2)

100 (30.7)

52 (29.2)

115 (22.8)

84 (25.8)

31 (17.4)

44 (8.7)

29 (8.9)

15 (8.4)

Charlson Comorbidity Index*‡

4.4 ± 2.4

4.6 ± 2.4

4.2 ± 2.5

ASA score*

2.8 ± 0.5

2.8 ± 1.4

2.8 ± 1.4

Dynamic

139 (27.6)

100 (30.7)

39 (21.9)

Static

365 (72.4)

226 (69.3)

139 (78.1)

Age of men* (yr)
Age of women* (yr)
Body mass index*

(kg/m2)

Musculoskeletal Infection Society classiﬁcation†
Infected
Non-infected
Previous operation before infection†

Comorbidities†
Diabetes mellitus
Rheumatoid arthritis

Type of spacer†

*The values are given as the mean and the standard deviation. †The values are given as the number of cases, with the percentage in parentheses.
‡This category was adjusted for age.

infection. Furthermore, there is considerable variability in the
literature with regard to how these studies deﬁne the success of
periprosthetic joint infection treatment, which could result in an
overestimation of the outcome measures. In addition, the study
populations often consist of a small cohort6.
To accurately depict the clinical course of two-stage exchange, an enhanced understanding of the interstage period is
needed. Although there are many studies that investigated the role
of spacer selection (static or dynamic) in either functional outcomes or infection control7-11, very few, if any, to our knowledge,
have investigated the clinical course following the ﬁrst stage of
a two-stage exchange arthroplasty. Furthermore, little is known
with regard to the fate of spacers in these patients undergoing a
two-stage exchange arthroplasty.
The aim of this study was to investigate the natural history
of resection arthroplasty and spacer implantation in patients
undergoing the ﬁrst stage of a planned two-stage exchange arthroplasty for treatment of periprosthetic joint infection.
Materials and Methods
Patient Demographic Characteristics

F

ollowing institutional review board approval, our institutional joint arthroplasty database was queried to identify 647 periprosthetic joint infections in patients who underwent resection arthroplasty and spacer insertion as part
of an intended two-stage exchange arthroplasty for suspected periprosthetic joint
infection. The period of study was from 1999 to 2013 and, during this time, 32,417
patients had undergone joint arthroplasty at our institution. Patients with a
megaprosthesis, prior native septic arthritis, prior two-stage exchange, or failed

one-stage exchange, or those who underwent spacer placement for reasons unrelated to periprosthetic joint infection were excluded. After exclusion of 143 cases
on the basis of the above criteria, a total of 504 periprosthetic joint infections (326
knees and 178 hips) in 482 patients were included in the ﬁnal cohort (Table I).

Component Specifications
At the time of initial spacer implantation, 365 periprosthetic joint infections
(72.4%) were treated with nonarticulating spacers and 139 periprosthetic joint
infections (27.6%) were treated with articulating spacers. The articulating spacers
were intraoperatively constructed primarily from prefabricated molds with endoskeleton implants (StageOne; Biomet, Warsaw, Indiana). The use of articulating
spacers increased during the study period from 0.0% in 1999 to 26.9% in 2013.
Dual antibiotics were in 97.6% of spacers, consisting almost entirely of 1 to 4 g per
pack (range of total grams, 1 to 12 g), to ensure activity against gram-positive and
gram-negative organisms; vancomycin was in 99.1% of spacers and tobramycin
was in 96.4% of spacers. In 2.4% of cases, the antibiotic utilized was an antifungal
or cephalosporin, which was based on the suspected organism or used if an allergy
to the standard antibiotic was present. The dosages increased during the time
course of the study, with the recent spacers regularly using 3 g of vancomycin and
2.4 to 3 g of tobramycin. Reimplantation was scheduled to occur following a
minimum of four weeks, but the duration of the interstage period was not otherwise designated. The timing of reimplantation was based on laboratory values
and clinical improvements. The erythrocyte sedimentation rate and C-reactive
protein values were examined for progressive sequential decreases. Prior to reimplantation, aspiration was not routinely performed. In addition, clinical signs
and improvement were monitored as a proxy for infection control, particularly
during the antibiotic-free period. At the time of reimplantation, spacers were
removed and repeat debridement was performed, followed by insertion of routine
revision-type prosthetic components utilizing antibiotic-loaded cement in total
knee arthroplasties and uncemented total hip arthroplasties. When cemented
components were used in the hip, antibiotic-loaded bone cement was utilized.
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TABLE II Outcomes and Complications Following Initial Spacer Implantation
All Periprosthetic Joint Infections
(N = 504)

Knee (N = 326)

Hip (N = 178)

56.2 (1.1 to 186.9)

59.7 (1.9 to 167.0)

49.1 (1.1 to 186.9)

4.2 (0.7 to 131.7)

4.1 (0.7 to 131.7)

4.4 (1.1 to 73.3)

Amputation

6 (1.2)

6 (1.8)

0 (0.0)

Girdlestone

5 (1.0)

0 (0.0)

5 (2.8)

Arthrodesis

4 (0.8)

4 (1.2)

0 (0.0)

72 (14.3)
6 (1.2)

38 (11.7)
5 (1.5)

34 (1.9)
1 (0.6)

Outcome Measure
Follow-up* (mo)
Duration of spacer* (mo)
Spacer complications and outcomes†

Spacer retention
Dislocation
Wound complications

30 (6.0)

24 (7.4)

6 (3.4)

Requirement for a second spacer

60 (11.9)

40 (12.3)

20 (11.2)

Persistent infection

44 (73.3)

27 (67.5)

17 (85.0)

Spacer dislocation

6 (10.0)

5 (12.5)

1 (5.0)

Wound problems

9 (15.0)

7 (17.5)

2 (10.0)

Tibial fracture

1 (1.7)

1 (2.5)

0 (0.0)

417 (82.7)
268 (81.4)

280 (85.9)
179 (81.4)

137 (77.0)
89 (81.7)

17 (23.6)

8 (21.1)

9 (26.5)

Reimplantation
Treatment success after reimplantation
Treatment success after spacer retention
Mortality after implantation of spacer†
Thirty days

6 (1.2)

3 (0.9)

3 (1.7)

Ninety days

13 (2.6)

8 (2.5)

5 (2.8)

One year

33 (6.5)

20 (6.1)

13 (7.3)

Two years

52 (10.3)

38 (11.7)

14 (7.9)

*The values are given as the mean, with the range in parentheses. †The values are given as the number of cases, with the percentage in
parentheses. Percentages for the four requirements for a second spacer were determined from the number of cases that required a second
spacer. Percentages for the two treatment success categories were determined from the number with reimplantation or the number with spacer
retention with a minimum of one year of follow-up.

TABLE III Organism Proﬁle at Initial Spacer Implantation*
All Periprosthetic Joint
Infections (N = 504)

Knee (N = 326)

Hip (N = 178)

Coagulase-negative Staphylococcus

84 (16.7)

60 (18.4)

24 (13.5)

Methicillin-sensitive Staphylococcus aureus

73 (14.5)

43 (13.2)

30 (16.9)

Streptococcus species

36 (7.1)

27 (8.3)

9 (5.1)

Enterococcus species

9 (1.8)

5 (1.5)

4 (2.2)

Gram-negative bacilli

33 (6.5)

23 (7.1)

10 (5.6)

Antibiotic resistant (vancomycin-resistant Enterococcus
or methicillin-resistant Staphylococcus aureus)

75 (14.9)

37 (11.3)

38 (21.3)

Other organism

19 (3.8)

16 (4.9)

3 (1.7)

Polymicrobial

39 (7.7)

24 (7.4)

15 (8.4)

136 (27.0)

91 (27.9)

45 (25.3)

Microorganism

Negative cultures

*The values are given as the number of cases, with the percentage in parentheses.
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TABLE IV Reimplantation Rate by Organism and Comorbidity*

No. of Cases

Overall Reimplantation
Rate (%)

No

459

Yes
Missing data

Factor

Knee Reimplantation
Rate (%)

Hip Reimplantation
Rate (%)

84.5

87.2

79.6

33

64.4

72.4

50.0

12

NA

NA

NA

Gram-negative

Antibiotic-resistant
Yes

P Value
0.002

>0.05
76

76.3

77.7

72.5

428

83.9

86.9

78.3

0

14

NA

NA

NA

1

26

84.6

83.3

85.7

2

55

96.4

100.0

92.0

3

97

90.7

93.2

86.8

4

121

88.4

96.2

74.4

5

79

79.7

81.4

75.0

6
‡7

43
69

65.1
63.8

56.4
50.0

66.7
72.1

Yes

44

70.5

69.0

73.3

No

447

83.9

87.8

77.0

13

NA

NA

NA

No
Charlson Comorbidity Index

<0.0001

Rheumatoid arthritis

Missing data

0.0347

Diabetes mellitus

>0.05

Yes

115

81.9

84.5

71.0

No

375

82.9

86.6

78.0

14

NA

NA

NA

Missing data
*NA = not applicable.

Outcome Variables

Statistical Analysis

A retrospective chart review was performed to extract patient demographic
characteristics and all of the relevant data, which included the following variables: surgical procedure details and the type of spacer placed, microbiological
data related to the infecting organism(s), and the clinical course of the patients
after resection arthroplasty and spacer placement. Details pertinent to subsequent operations, including the reimplantation, were also extracted.
From the institutional database, queries were performed to obtain information on patient comorbidities including body mass index, diabetes mellitus, rheumatoid arthritis, Charlson Comorbidity Index, and American Society of
12
Anesthesiologists (ASA) classiﬁcation . The Charlson Comorbidity Index pro13
vides a method of quantifying overall health and is predictive of mortality . Data
related to mortality were ascertained from the clinical records and the status of
each patient was checked using the Social Security Index, a governmental mortality search engine based on Social Security number; however, this tool does not
provide the cause of death. Treatment success was judged according to criteria
based on the Delphi international multidisciplinary consensus: infection eradication characterized by a healed wound without drainage, ﬁstula, or pain and
no infection recurrence; no occurrence of periprosthetic joint infection-related
mortality (e.g., sepsis, necrotizing fasciitis); and no subsequent surgical inter14
vention for infection after reimplantation surgery . Given that the Delphi criteria do not account for patients who do not undergo the reimplantation phase of
the two-stage exchange, treatment success also included no subsequent surgical
intervention for infection after spacer implantation in patients with a retained
spacer and no mortality related to the infection.

Differences in the reimplantation rate between gram-negative and grampositive organisms and between resistant and susceptible organisms were calculated with use of the Fisher exact test. A logistic regression was used to assess the
correlation between the Charlson Comorbidity Index and the reimplantation
rate. The number of surgeries and spacers were analyzed with use of the Wilcoxon
test for binary comparison. The total number of surgeries was compared with the
patient’s comorbidities, including ASA score, Charlson Comorbidity Index, and
body mass index. Signiﬁcance was set at p < 0.05.

Source of Funding
There was no external funding source for this study.

Results
eimplantation occurred in 417 (82.7%) of 504 cases. The
mean duration from resection arthroplasty to reimplantation was 4.2 months (median, 2.7 months [range, 0.7 to 131.7
months]) (Table II). The mean follow-up duration after spacer
insertion was 57.4 months for patients who underwent reimplantation and 42.7 months for those who did not undergo reimplantation. Sixty (11.9%) of 504 cases required a mean of 1.1
spacer exchanges (range, one to six spacer exchanges) in the interstage period between initial resection arthroplasty and eventual
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Fig. 1

Flowchart depicting the outcomes of the ﬁnal cohort. PJI = periprosthetic joint infection.

reimplantation (Fig. 1). The reasons for requiring additional
spacer exchanges included persistent infection (forty-four cases
[73.3%]), spacer dislocation (six cases [10%]), wound-related
problems (nine cases [15%]), and fracture of the tibia (one case
[1.7%]). The reimplantation rate was 87.1% for articulating
spacers and 81.2% for static spacers, and the duration to reimplantation was 4.3 months for articulating spacers and 4.0 months
for static spacers. There was no difference in the reimplantation
rate (p = 0.146) or treatment success rate (p = 0.730) between the
types of spacers.
Of the cases undergoing reimplantation, 329 joints (78.9%)
had a minimum one-year follow-up. Treatment success was
81.4% for the entire cohort, 81.4% for knees, and 81.7% for hips
(Fig. 2). Following reimplantation, the mean follow-up duration
was 57.0 months in cases with treatment success and 50.4 months
in cases with failure. The mean number of surgeries between the
resection arthroplasty with spacer insertion and the reimplantation was 1.3 surgeries (range, one to six surgeries), which included
additional spacer exchanges, irrigation and debridement, and
reoperation for wound-related complications. Of those eightyseven cases that did not undergo second-stage reimplantation, six
required amputation (6.9%), ﬁve (5.7%) underwent a Girdlestone
procedure, four (4.6%) underwent arthrodesis, and seventy-two
(82.8%) retained the spacer. Of the seventy-two cases that retained
the spacer, treatment success was 23.6% (seventeen cases) at a
minimum one-year follow-up (Fig. 1).
Of the seventy-two cases of retained spacers, nineteen
(26.4%) were lost to follow-up after the decision was made to use
the retained spacer as the deﬁnitive treatment, leaving ﬁfty-three
cases. When excluding cases lost to follow-up, treatment success
was 32.1% (seventeen cases). In thirty-six cases (50.0%) with retained spacers, the patients died before the second stage at a mean
time of 38.3 months (range, 0.4 to 127.5 months), with ﬁve of those
deaths occurring during the initial hospitalization for spacer in-

sertion; we conﬁrmed that mortality in the latter ﬁve cases was
related to the infection. The major reasons for a retained spacer
among the seventy-two cases were no desire for reimplantation
(2.8% [two cases]) or being unﬁt for the surgical procedure (20.8%
[ﬁfteen cases]) for a variety of reasons (e.g., severe bone loss and
non-healing ulcers).

Fig. 2

Kaplan-Meier survivorship curve with treatment failure as an end point. The
dashed lines indicate the 95% conﬁdence interval.
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The overall incidence of mortality for the cohort was 1.2%
(six cases) within thirty days, 2.6% (thirteen cases) within ninety
days, 6.5% (thirty-three cases) within one year, and 10.3% (ﬁftytwo cases) within two years. In comparison, the death rate of
patients who are sixty-ﬁve to seventy-four years of age in the
United States is 2.0%15. The most common infecting organisms
at the time of resection arthroplasty and spacer insertion were
coagulase-negative Staphylococcus (16.7%) and methicillinsensitive Staphylococcus aureus (14.5%) (Table III). For patients
with reinfection, 22.5% were infected with the same organism as
that identiﬁed at the time of initial resection arthroplasty. A
signiﬁcantly increased number of interim spacer exchanges were
performed in the seventy-six patients who had periprosthetic
joint infection by a resistant organism(s) (p = 0.02), but no
difference in reimplantation rate was observed (Table IV). In
addition, patients with gram-negative bacteria demonstrated a
lower reimplantation rate than those infected with gram-positive
bacteria (p = 0.002).
When stratiﬁed by comorbidities, increased Charlson Comorbidity Index (p < 0.0001) and presence of rheumatoid arthritis (p = 0.03) were associated with a lower reimplantation rate
(Table IV). Furthermore, the total number of procedures was
signiﬁcantly higher when associated with higher body mass index
(p = 0.006).
Discussion
he success of two-stage exchange arthroplasty for the treatment of chronic periprosthetic joint infection has been reported to approach or to exceed 80% in the majority of studies16-22.
However, there is a widespread heterogeneity on the reporting
of the clinical outcomes of two-stage exchange arthroplasty. The
most important fact is that the deﬁnition of success has varied in
these reports. The lack of consensus with regard to what constitutes a successful treatment outcome for periprosthetic joint
infection makes it difﬁcult to compare the outcomes between
studies and ultimately between different treatment strategies. This
has led to the development of a multidisciplinary consensus to
better deﬁne success14. However, despite the availability of an acceptable deﬁnition for success, it is not known whether success
should take into account patients who had a failure after the ﬁrststage surgical procedure and never underwent reimplantation for
a variety of reasons.
The majority of studies showing the outcome of two-stage
exchange arthroplasty do not take into account the attrition that
occurs between the two stages and arguably overestimate the
success of this surgical procedure. Although there are a variety of
reasons for the attrition between stages, one sobering recognition is that the proportion of patients who die after the initial
resection arthroplasty is not small1,23.
This study, speciﬁcally designed to evaluate the clinical
course of patients in between two stages, demonstrated that almost
one-ﬁfth of patients who underwent resection arthroplasty and
spacer insertion did not undergo a subsequent reimplantation.
Within the literature, there is considerable variation in the reimplantation rates following explantation, ranging from 28.6%24
to 100%25-29, and most studies have demonstrated reimplantation
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rates above 80%1,2,5,30-34. Failure to reimplant may occur for a variety
of reasons, including mortality, medical comorbidity, patients lost
to follow-up, patients satisﬁed with their current level of function
in the setting of a retained spacer19, and persistent infection that
may ultimately result in deﬁnitive treatment with amputation,
arthrodesis, or lifetime antibiotic suppression. Therefore, the reimplantation rates within the literature and in the present study
suggest that the number of patients who fail to undergo reimplantation is not inconsequential and that reported outcomes
following completion of the second stage neglect the nearly 20% of
treatment failures in the interstage period.
We suggest that the success of two-stage treatment be considered from the point of initial spacer implantation rather than
following reimplantation to account for failures that occur in the
interstage period. For example, Berend et al. reported a success rate
of 83% following reimplantation in a study of 205 hips. However,
when accounting for a reimplantation rate of 92%, the rate of
infection control following initial spacer implantation dropped to
77%1. Another study of 130 patients with periprosthetic joint infection demonstrated a 95% rate of eradication following reimplantation, but only a 68% rate when taking into account a
reimplantation rate of 84.6% and those who either had been lost to
follow-up or had died28. Despite having a lower reimplantation
rate, the ﬁrst stage as a starting point better represents the actual
clinical course and explains the seemingly low infection eradication
rates reported in the current study and previous reports from our
institution35-38.
It is also important to point out that, even for patients
in the present study who ultimately underwent reimplantation,
many underwent spacer exchange or surgical intervention for
wound-related problems in the interstage period, with all of the
inherent risks of added surgical procedures19,39,40. In nearly one of
ﬁve patients, the intended two-stage exchange never occurred,
with patients requiring arthrodesis or amputation or resorting to
living with the implanted spacers. When taking into account the
failures that occurred in the interstage period in addition to the
patients who were reinfected after reimplantation, it becomes
clear that the failure rate in the interstage period approaches the
reinfection rate that is usually seen with the two-stage exchange,
at around 17%.
Although several studies have investigated the impact of
organism type and resistance proﬁle on the eventual outcome of
two-stage exchange arthroplasty, we are unaware of any studies
investigating the role of microorganisms in the interstage period.
We noted that patients with periprosthetic joint infection caused
by resistant organisms and gram-negative organisms had a more
complicated course requiring additional surgeries, and fewer of
these patients underwent subsequent reimplantation (Table IV).
The latter may relate to the fact that surgical management of
patients with periprosthetic joint infection caused by more virulent organisms is more challenging 32,36,41,42. This is an important
ﬁnding because patients with a culture-negative infection or resistant organisms are typically managed by two-stage exchange;
however, our study demonstrates that these infections are still
associated with a reduced reimplantation rate. In addition to the
type of infecting organism, the overall medical comorbidity of the
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patients also inﬂuenced the reimplantation rate and number of
surgical procedures in the interstage period, with sicker patients
having a more protracted interstage course. Surgeons should be
aware that these factors, the type of infecting organism and comorbid medical conditions, might inﬂuence the likelihood of a
patient completing both stages of a two-stage exchange.
There were limitations to the current study. The retrospective nature of the study, with all of the inherent limitations
of such a study design, may have allowed for the introduction of
bias. In addition, the current study intentionally did not include
evaluation of radiographic or functional outcomes, which may be
seen as a potential weakness. Furthermore, despite all our efforts,
including calling all patients as part of another study, some patients were lost to follow-up or did not have long-term follow-up.
However, all patients were included regardless of the follow-up
to prevent an overestimation of the results and to allow a more
realistic picture of the actual clinical course. In addition, some
may argue that reinfection by a different organism than the initial
infection, which happened in the majority (77.5%) of the cases
of reinfection, should not be attributed to failure of the initial
treatment. However, it is possible that the organisms cultured at
the time of failure were in fact present at the time of the initial
periprosthetic joint infection but were not captured by the culture technique, rather than representing a new infection. Because
the latter possibility cannot be ruled out, we believe that an infection with a different organism may still be attributed to failure
of the initial two-stage exchange. In addition, subsequent surgical
procedure for infection and mortality were used to evaluate
treatment success, and these do not require a recurrent organism
to be present according to the Delphi consensus criteria14. Additionally, infection-related mortality was difﬁcult to conﬁrm in
deaths that occurred outside of a hospital. Although the date of
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death was known in these patients, the precise cause of death
could not be determined. Lastly, it should be noted that there was
not a clear reimplantation protocol and that some failures may
potentially have been caused by variations in the reimplantation
protocol, for example, returning to the operating room too soon
or differences in an antibiotic-free period. This inconsistency can
be attributed to the several surgeons involved in this study and
the lack of current guidelines and literature for determining the
optimal time for reimplantation.
Despite the aforementioned limitations, this study highlights
the fact that the commonly held belief that two-stage exchange
arthroplasty carries a high success rate for eradication of periprosthetic joint infection may need to be reexamined. A considerable number of patients undergoing resection arthroplasty and
spacer insertion do not undergo subsequent reimplantation for
a variety of reasons, and many are subjected to interim surgical
procedures. Of those who undergo reimplantation, nearly one-ﬁfth
experience a failure later because of persistence of infection or
reinfection. The future management of patients with periprosthetic
joint infection needs to change as current strategies, which have a
high burden on the patient and society, are far from perfect. n
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